10-Q: Pfizer Reports Q1 2026 Results: Revenue Up 5%, Driven by Key Drugs

Pfizer Inc. announced its first quarter 2026 financial results, showing a 5% increase in total revenues to $14.5 billion, driven by strong performance in key biopharmaceutical products.

Summary

• Pfizer reported total revenues of $14.5 billion for the first quarter of 2026, a 5% increase compared to $13.7 billion in the same period of 2025. This growth was driven by a 7% operational increase excluding COVID-19 products.
• Net income attributable to Pfizer Inc. common shareholders was $2.7 billion, or $0.47 per diluted share, a decrease from $3.0 billion, or $0.52 per diluted share, in the prior year's quarter.
• The company's Biopharma segment remains its sole reportable segment, generating $14.2 billion in revenues.
• Key product revenues showed significant growth for Padcev (up 39%), Nurtec ODT/Vydura (up 42%), and Abrysvo (up 31%).
• Revenues from Comirnaty and Paxlovid saw substantial declines, down 59% and 63% respectively, reflecting lower demand and reduced government purchases.
• The company is implementing cost-reduction programs, including the 'Realigning Our Cost Base Program' and 'Manufacturing Optimization Program', aiming for significant cost savings.
• Pfizer completed the exit of its investment in ViiV for $1.875 billion on March 31, 2026.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing, with solid revenue growth driven by key biopharmaceutical products, but tempered by declining COVID-19 product sales and a decrease in net income.

Positives

• Total revenues increased by 5% to $14.5 billion, with a 7% operational increase excluding COVID-19 products.
• Strong revenue growth was observed in key products such as Padcev (up 39%), Nurtec ODT/Vydura (up 42%), and Abrysvo (up 31%).
• The Biopharma segment continues to be the primary driver of revenue, with total revenues of $14.2 billion.
• The company is actively managing its cost base through 'Realigning Our Cost Base Program' and 'Manufacturing Optimization Program', targeting substantial savings.
• Pfizer received $1.875 billion in cash proceeds from the sale of its investment in ViiV.
• Cash provided by operating activities increased to $2.6 billion from $2.3 billion in the prior year.

Negatives

• Net income attributable to Pfizer Inc. common shareholders decreased to $2.7 billion from $3.0 billion in the prior year.
• Earnings per diluted share decreased to $0.47 from $0.52 year-over-year.
• Revenues from Comirnaty and Paxlovid experienced significant declines of 59% and 63% respectively.
• Prevnar family revenues decreased by 1% operationally, primarily due to lower vaccination rates and market share erosion in the U.S.
• Ibrance revenues decreased by 1% operationally, mainly due to lower net price in the U.S. and unfavorable buying patterns.
• Xtandi revenues decreased by 3% operationally, primarily driven by lower net price in the U.S.

Risks

• The loss, expiration or invalidation of intellectual property rights, patent litigation settlements and judgments, and the expiration of co-promotion and licensing rights could materially adversely affect revenues.
• Pricing and access pressures from governments globally and private third-party payors in the U.S. continue to impact global operations.
• The Inflation Reduction Act (IRA) and its Medicare Drug Price Negotiation Program (MDPNP) will impact pricing for key drugs like Eliquis, Ibrance, Xtandi, and Xeljanz.
• Changes to the Medicaid Drug Rebate Program or the 340B Program could materially impact the business.
• New and potential policy, regulatory or other changes from the U.S. Presidential administration, Congress and states could adversely affect business, earnings, cash flows, liquidity and financial guidance.
• Product supply disruptions, shortages, or recalls could occur.
• Geopolitical and trade developments could impact supply chains and costs.
• The company faces ongoing patent litigation for several key products, including Vyndaqel-Vyndamax, Oxbryta, Nurtec, Xtandi, Cibinqo, Comirnaty, and Paxlovid.
• Product liability and other product-related litigation, including asbestos and Zantac-related cases, continue to pose risks.
• Government investigations, including those related to India operations and antitrust matters, could result in substantial fines, penalties, or limitations on business operations.
• The company anticipates a significant reduction in revenue from patent-based or regulatory exclusivity expiries between 2026 and 2030, with an estimated unfavorable revenue impact of $1.5 billion in 2026.

Future Outlook

The company anticipates a significant reduction in revenue from patent-based or regulatory exclusivity expiries between 2026 and 2030, with an estimated unfavorable revenue impact of $1.5 billion in 2026. Pfizer is focused on advancing its product pipeline, maximizing existing product value, and pursuing strategic business development activities. Cost-reduction programs are expected to yield significant savings. The company expects to continue to de-lever its balance sheet and maintain a balanced capital allocation strategy.

Management Comments

• The increase in Income from continuing operations before provision/(benefit) for taxes on income was primarily due to higher revenues and a decrease in Restructuring charges and certain acquisition-related costs, partially offset by increases in Cost of sales and Research and development expenses.
• Selling, informational and administrative expenses decreased primarily reflecting a decrease in marketing and promotional spend and lower spending in corporate enabling functions.
• Research and development expenses increased driven primarily by an increase in spending in certain oncology and obesity product candidates.
• The 'Realigning Our Cost Base Program' is expected to deliver total net cost savings of approximately $5.7 billion through 2026.
• The first phase of the 'Manufacturing Optimization Program' is on track to deliver approximately $1.5 billion in net cost savings by the end of 2027.
• The Metsera acquisition is expected to generate approximately $600 million of annual cost synergies by the end of 2026.

Industry Context

StockSavvy.ai notes that Pfizer's Q1 2026 results reflect the ongoing challenges and opportunities within the biopharmaceutical industry, including the impact of patent expiries, increasing pricing pressures, and the continued importance of R&D for pipeline growth. The company's strategic focus on key therapeutic areas and cost management aligns with industry trends.

Comparison to Industry Standards

• Pfizer's revenue growth of 5% in Q1 2026, excluding COVID-19 products, shows a 7% operational increase, which is a solid performance in a competitive pharmaceutical market where growth is often driven by new product launches and market share gains.
• The decline in COVID-19 product revenues (Comirnaty and Paxlovid) is a trend observed across the industry as the pandemic's acute phase subsides and demand normalizes.
• The company's investment in R&D, with expenses increasing by $287 million, reflects the industry's reliance on innovation to offset patent cliffs and maintain long-term growth.
• The implementation of cost-reduction programs is a common strategy in the pharmaceutical sector to improve margins and fund R&D, especially in anticipation of generic competition.
• Pfizer's effective tax rate of 14.6% for continuing operations in Q1 2026 is within a range that many large pharmaceutical companies aim for, though it is higher than the negative rate in the prior year due to specific tax items.

Legal Proceedings

• Patent litigation is ongoing for Vyndaqel-Vyndamax, Oxbryta, Nurtec, Xtandi, Cibinqo, Comirnaty, and Paxlovid, with various outcomes and settlements mentioned.
• Product liability litigation, including asbestos and Zantac-related cases, continues, with some cases dismissed and others settled.
• Government investigations are ongoing, including inquiries related to India operations and antitrust litigation concerning Greenstone.
• Pfizer and BioNTech are involved in breach of contract proceedings against Poland and Romania regarding COVID-19 vaccine orders.
• The company is subject to various other commercial and environmental matters, including those related to former subsidiaries and acquired companies.

Stakeholder Impact

• Shareholders: Potential for continued dividend payments and future share repurchases, but also face reduced net income and EPS compared to the prior year.
• Employees: Impacted by cost-reduction programs, which may include severance costs, but also by ongoing R&D and business development initiatives.
• Customers: Benefit from continued access to Pfizer's diverse product portfolio, including new treatments and vaccines.
• Suppliers: Continued business relationships, with some suppliers participating in voluntary supply chain finance agreements.
• Creditors: Pfizer's strong credit ratings and access to revolving credit facilities indicate continued financial stability.

Next Steps

• Continue to execute on cost-reduction programs ('Realigning Our Cost Base Program' and 'Manufacturing Optimization Program').
• Advance product pipeline and maximize value of existing products through R&D and business development.
• Monitor and manage the impact of patent expiries and generic/biosimilar competition.
• Navigate pricing and access pressures from governments and payors, including the impact of the IRA.
• Complete the reallocation of goodwill within the Biopharma segment.
• Continue to monitor and adapt to evolving global economic, geopolitical, and regulatory environments.

Key Dates

Recommendation

Pfizer's Q1 2026 results show solid operational revenue growth driven by key biopharmaceutical products, but this is offset by declining COVID-19 product sales and a decrease in net income and EPS. The company faces significant headwinds from patent expiries and increasing pricing pressures. While cost-saving initiatives and a strong R&D pipeline offer some optimism, the near-term outlook is mixed, warranting a 'hold' recommendation until more clarity emerges on the impact of patent cliffs and the success of new product launches.

Keywords

Pfizer, 10-Q, Quarterly Report, Biopharma, Pharmaceuticals, Revenues, Net Income, Padcev, Nurtec ODT, Abrysvo, Comirnaty, Paxlovid, Cost Reduction, ViiV Investment